CIK 0001515673 · Large accelerated filer
Ultragenyx Pharmaceutical Inc.
Sign in to watch- Ticker
- RARE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 272546083
- Phone
- 415-483-8800
- Business address
- 60 LEVERONI COURT, NOVATO, CA, 94949
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $127,561
- in 3 filings, $17K under 10b5-1 plans
Net −$127,561. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-01 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Shares withheld for taxes | −121 | $53.69 | $6K | 41,721 |
| 2024-03-01 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Sale | −341 | $53.76 | $18K | 41,380 |
| 2024-03-01 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) | +8,200 | 8,200 | ||
| 2024-03-01 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) | +2,351 | 2,351 | ||
| 2024-03-01 | Crombez Eric EVP and Chief Medical Officer | Grant or award | +19,400 | 49,912 | ||
| 2024-03-01 | Crombez Eric EVP and Chief Medical Officer | Sale | −1,238 | $53.76 | $67K | 48,927 |
| 2024-03-01 | Crombez Eric EVP and Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +34,200 | 34,200 | ||
| 2024-03-01 | Crombez Eric EVP and Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +2,351 | 2,351 | ||
| 2024-03-01 | Harris Erik EVP & Chief Commercial Officer | Grant or award | +19,400 | 70,681 | ||
| 2024-03-01 | Harris Erik EVP & Chief Commercial Officer | Grant or award | +957 | 71,638 | ||
| 2024-03-01 | Harris Erik EVP & Chief Commercial Officer | Sale | −4,768 | $53.76 | $256K | 67,163 |
| 2024-03-01 | Harris Erik EVP & Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +34,200 | 34,200 | ||
| 2024-03-01 | KAKKIS EMIL D President & CEO | Grant or award | +38,428 | 578,198 | ||
| 2024-03-01 | KAKKIS EMIL D President & CEO | Shares withheld for taxes | −17,417 | $53.69 | $935K | 560,781 |
| 2024-03-01 | KAKKIS EMIL D President & CEO | Grant or award | +3,132 | 563,913 | ||
| 2024-03-01 | KAKKIS EMIL D President & CEO | Grant or award · Stock Option (Right to Buy) | +70,094 | 70,094 | ||
| 2024-02-07 | KAKKIS EMIL D President & CEO | Sale | −30,000 | $45.00 | $1.4M | 539,770 |
| 2024-01-02 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Option exercise | +3,000 | $21.00 | $63K | 27,892 |
| 2024-01-02 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Option exercise · Stock Option (Right to Buy) | −3,000 | 0 | ||
| 2023-12-29 | KAKKIS EMIL D President & CEO | Sale | −30,000 | $47.87 | $1.4M | 569,770 |
Page 10 of 11 · 204 trades